A Case Study of De-identifying a Clinical Trial Data Set
Interested in learning more about de-identifying a clinical trial data set? Don’t miss this webinar! A Case Study of De-identifying…
PHI – Managing the Risks, Reaping Potential Rewards
Unlocking PHI for secondary purposes is possible – when using a risk-based, defensible approach Don’t miss our latest webinar, PHI…
21st Century Cures Act Implications
The 21st Century Cures Act passed the House of Representatives easily, and is now headed to the Senate. This bill…
Methods for Risk-based De-id of CSRs
Clinical study reports have a wealth of insight – unlock it with a risk-based de-identification strategy. This webinar explores how to accomplish this.
Webinar: De-identification 201
Let the experts guide you through the existing standards and regulations when it comes to de-identifying PHI for secondary purposes. Minimize risk and maximize utility when it comes to health data.
Experiences Building a RWE Database
Privacy Analytics’ de-identified EMR data so that it could be safely utilized without putting patient privacy at risk. IMS Brogan…
Making the business case for de-identification for clinical trials, Privacy Analytics describe a risk-based approach to ensure granular data and minimal risk of re-identification of clinical trial data.
How to Safeguard PHI Webinar
How do you manage the risks associated with the release of protected health information? Based on a real-use case, Privacy Analytics will demonstrate the risks and how to manage them. From public to private data release, there is a more effective way to de-identify data.
Q and A with the Experts March Edition
Round Two of our Ask an Expert Series. The industry experts answer your questions about preferred methods and standards, longitudinal data, ICD-10 codes and more.
Re-identification Risks for Credit Card Data
A recent article highlighted that is was possible to re-identify financial data that has been de-identified. The experts reveal that re-identification is next to impossible when you apply real, risk-based de-identification: a strong standard they encourage the financial section to consider. Featuring guests Christin McMeley and Brian Hurh, Davis Wright Tremaine.
Responsible De-identification of Clinical Trial Data
Best practices around clinical trial data sharing The number of clinical trial data sets that are available for secondary analysis…
De-identification 101 Webinar
Join Privacy Analytics for a high level introduction of de-identification and data masking. We will compare the HIPAA privacy rule mechanisms known as Safe Harbor and Expert Determination Methods in terms of data quality and risk of re-identification.